title: [Indirect, population effect of mass pneumococcal vaccinations (PCV7) on all-cause pneumonia incidence in Kielce, Poland].
abstract: In these article they made analysis of indirect, population effects of mass, free of charge, pneumococcal vaccinations (PCV7) on all-cause pneumonia incidence in Kielce, Poland. The strongest and significant fall (p=0.00079) in all-cause pneumonia incidence in the analyzed period 2005-2009 compared with remaining groups were observed in the group of children under 2 of years of life. He amounted to the 74% (around 25/1000 in 2005; 6/1000 in 2009). In the entire ancient group 0-29, embracing children under 2 yrs of life the fall of pneumonia incidence rate amounted to the 48% (from 2.8/1000 in 2005; 1.5/1000 in 2009). In the age 65+ group the fall in the incidence amounted to the 45% (19/1000 in 2005; <11/1000 in 2009 r.). At the moment they didn't observe, of such a fall in age groups 30-49 yrs and 50-64 yrs. Presented results are pointing population effectiveness of applied in Kielce mass vaccination in a 2+1 scheme. Analyzing only pneumonia requiring the hospitalization they tried at work to estimate, in the definitely simplified way, financial effects of mass pneumococcal vaccination in Kielce. Analysis showed at children up to 2 yrs frugalities of the row of the 174,420 zloty annually. In the group above 1 year of life analogous analysis showed frugalities of row 789,480 zloty. Results presented by us should, in our opinion, to induce decision-makers for free of charge mass pneumococcal vaccinations to entire Poland.
authors: NZOZ Promed w Kielcach.
authors: Marian
authors: M
authors: Patrzałek
authors: Piotr
authors: P
authors: Albrecht
authors: Maciej
authors: M
authors: Sobczyński
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015984:Causality; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000191:economics / Q000706:statistics & numerical data; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D017053:Infection Control / Q000191:economics* / Q000706:statistics & numerical data; D008297:Male; D008586:Meningitis, Pneumococcal / Q000191:economics / Q000453:epidemiology; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology* / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000191:economics* / Q000276:immunology; D011018:Pneumonia, Pneumococcal / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control; D011044:Poland / Q000453:epidemiology; D018074:Vaccines, Conjugate / Q000191:economics / Q000276:immunology
chemical_list: D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate